SanaClis
ActiveThe computed 12-month bankruptcy probability of SanaClis is 1.8% (moderate). The annual accounts of SanaClis for fiscal year 2024 show a net loss of 116% of total assets. The 2024 annual accounts show equity of €2k and a net result of €-48k. Its solvency ranks better than 21% of 226 sector peers (fiscal year 2024). The company has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2024
38
/ 100
Weak
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes
Profitability0
Solvency31
Growth-
Track record67
Bankruptcy probability, 12 months
1.8%
Moderate
0%0.5%1.5%4%10%≥ 25%
No publishable credit limit; credit only on tighter terms
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity tight (current ratio 1.09; short-term debt: 69.4% and cash: 30.8% of total assets), and 94% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation dateAge against the risk zone
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
6%
Return on assets
-116%
Age of the figures
21 mo
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Sector 72
lower
← fewer bankruptcies
more bankruptcies →
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 21% of 226 sector peers (2024).
NBB · sector comparisonPosition among 226 sector peers
Solvency
better than 21%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 20-06-2025, 41 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2024
41 d early
← before the deadline
after the deadline →
Financials · fiscal year 2024, abbreviated schema
Equity
€2k
Total assets
€41k
Net result
€-48k
Working capital
€2k
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Balance-sheet composition
Assets €38k
Fixed assets
€7k
Current assets
€31k
Equity and liabilities €41k
Equity
€2k
Debt
€39k
Debt finances 94.0% of the balance-sheet total.
Key figures and ratios
EBITDA
€-46k
Cash flow
€-47k
Solvency
6.0%
Current ratio
1.09
Quick ratio
1.09
Debt / equity
15.62
ROA
-116.0%
Interest coverage
-44.74
Debt
€39k
Debt ≤ 1 year
€28k
Debt > 1 year
€10k
Income taxes
€58
Staff costs
€85k
A ratio outside any meaningful range has been withheld (balance sheet total €41k, equity €2k).
Filed annual accounts
As filed with the NBB · 2024
Balance sheet
Code2024
Assets
Total assets20/58€41k
Formation expenses20€3k
Fixed assets21/28€7k
Financial fixed assets28€7k
Current assets29/58€31k
Amounts receivable within one year40/41€12k
Trade receivables40€9k
Other amounts receivable41€3k
Cash at bank and in hand54/58€13k
Deferred charges and accrued income490/1€7k
Equity and liabilities
Total equity and liabilities10/49€41k
Equity10/15€2k
Contributions10/11€50k
Profit (loss) carried forward14€-48k
Amounts payable17/49€39k
Amounts payable after more than one year17€10k
Financial debts170/4€10k
Amounts payable within one year42/48€28k
Trade debts44€11k
Suppliers440/4€11k
Taxes, remuneration and social security45€17k
Taxes450/3€58
Remuneration and social security454/9€17k
Accrued charges and deferred income492/3€72
Income statement
Code2024
Remuneration, social security and pensions62€85k
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€326
Gross operating margin9900€38k
Operating profit (loss)9901€-46k
Financial charges65/66B€1k
Recurring financial charges65€1k
Profit (loss) for the period before taxes9903€-47k
Income taxes67/77€58
Profit (loss) for the period9904€-48k
Profit (loss) for the period to be appropriated9905€-48k
Appropriation of the result
Profit (loss) to be appropriated9906€-48k
Social balance
Average headcount (FTE)90871.0
The notes to these accounts (9 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2025
20-06
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
NBB filing
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Diepenbeek · 1 establishment unit since 2024
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Wetenschapspark 113590 DiepenbeekGround area
8,022 m²
Building footprint
822 m²
Volume, LiDAR
2,712 m³
Parcel 71011A0181/00R000, Flanders · tallest building 4.1 m, ±1 floor. Linked by address, not a title deed.
1 establishment unit
SanaClis
since 20242.362.329.783
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 71011A0181/00R000 | Flanders | 8,022 m² | 1 · 822 m² | 4.1 m · 1 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Education and Edition for Science
BE 0750.847.207
Schaarbeek · Eq €2k
Obvio Laboratories
BE 0763.445.923
Ukkel · Eq €3k
Formac Pharmaceuticals
BE 0892.914.395
Leuven · Eq €2k
CYTéVIE
BE 0474.812.921
Comblain-au-Pont · Eq €2k
Minerva Pharma Consulting
BE 0798.842.609
Keerbergen · Eq €3k
Of 1,177 companies in sector 72109 we hold annual accounts for 715. 88 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded12-06-2024
Fiscal year end31-12
Activities, NACEBEL
72101Research and development on biotechnology
72109Other research and development on natural sciences
Sources
Crossroads Bank for EnterprisesNational Bank · 1 filingAddress and cadastre registers
Data from official sources, last processed on 19-09-2026. Scores and ratios are computed by Checked and are not a credit decision.